← All trials
NCT06254690
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2024
- Primary completion
- Nov 1, 2026
- Completion date
- Dec 1, 2026
- First posted
- Feb 12, 2024
- Last posted
- Feb 12, 2024
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nanjing Medical UniversityLead sponsor
- Soochow UniversityCollaborator
- Xuzhou Medical UniversityCollaborator
- Jiangsu UniversityCollaborator
- Yancheng First People's HospitalCollaborator
- Jiangnan UniversityCollaborator
- Huai'an First People's HospitalCollaborator
- Nanjing Medical UniversityOfficial
- Anhui Medical UniversityCollaborator
- Jingjiang People's HospitalCollaborator
- Nanjing UniversityCollaborator
- Southeast UniversityCollaborator
- Nantong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.